Method of Local Administration of rIL-2 and its Efficacy

Abstract

Recombinant interleukin-2 (rIL-2) has been administered locally in 20 patients with head and neck cancer. Two complete response (CR) in lower lip cancer and one partial response (PR) in lingual cancer has been obtained.
Intraarterial chemotherapy, performed subsequent to the local use of rIL-2 results in a dramatic decrease in tumor size within a short time, and a high frequency of CR cases is observed.
Local use of rIL-2 is beneficial for treatment of head and neck cancers, and neo-adjuvant immunochemotherapy combining locally used rIL-2 and arterially infused anticancer drugs plays animportance role in a multidisciplinary treatment for these cancers.